Showing results (1-10 of 927) with videos related to
Sort By:
Pageof 93
Headache|January 25, 2005
Migraine therapy: a survey of pharmacists' knowledge, attitudes, and practice patternsRichard G Wenzel, Richard B Lipton, Merle L Diamond, et al.The Journal of Headache and Pain|February 8, 2022
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trialsRichard B Lipton, Larry Charleston, Cristina Tassorelli, et al.Headache|May 20, 2021
Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcomeRichard B Lipton, David W Dodick, Jessica Ailani, et al.Headache|August 31, 2020
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic MigraineCarrie R Houts, R J Wirth, James S McGinley, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 20, 2020
Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 studyCarrie R Houts, James S McGinley, R J Wirth, et al.The Journal of Headache and Pain|July 28, 2022
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF studyRoger Cady, Richard B Lipton, Dawn C Buse, et al.Neurology|January 23, 2015
Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraineRichard B Lipton, Kristina M Fanning, Daniel Serrano, et al.Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.Headache|April 23, 2002
Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysisRoger CadyPageof 93